Approval · Notice of Compliance 36437 · 2025
RADICAVA: Notice of Compliance 36437
Issued November 27, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36437
- Date
- November 27, 2025
- Company
- Mitsubishi Tanabe Pharma CorporationChuo-Ku, Osaka-Fu, Japan
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Removal of route of administration: [Radicava IV Injection]. Product Monograph reformatted to the Master Template. Update to Patient Medication Information. Update to package insert. Update to Instructions for Use
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RADICAVA | Not yet assigned | — |
Medicinal ingredients
- EDARAVONE 105 MG per 5ML